Bayer (BAYN.DE)

Executive Summary

Bayer AG is a diversified life sciences leader operating across Pharmaceuticals, Consumer Health, and Crop Science. Its pharmaceutical portfolio includes blockbusters like Xarelto (rivaroxaban) and Eylea (aflibercept), while Crop Science faces ongoing litigation related to glyphosate-based herbicides. Despite legal overhangs, Bayer’s R&D pipeline targets high-unmet-need areas, including women's health and cardiovascular disease. The company’s scale and diversified revenue streams provide resilience, but near-term growth hinges on pipeline execution and legal resolutions. In 2026, Bayer aims to advance key late-stage assets while managing significant litigation costs. The conviction score of 70 reflects a balanced view between pipeline opportunities and persistent legal uncertainties, supported by Bayer's strong commercial infrastructure and global reach.

Upcoming Catalysts (preview)

• Q3 2026Elinzanetant Phase 3 data readout (Oasis 3) for vasomotor symptoms80% success
• Q4 2026Asundexian Phase 3 results (Oceanic-AF) for stroke prevention in atrial fibrillation60% success
• Q4 2026Key Roundup litigation ruling or settlement update50% success